Name: Erly Pen
SKU: 23974
Availability: InStock

📋 Product Overview Table

🌐 Specification	🧾 Details
💊 Active Ingredient	Liraglutide
🧪 Strength	6 mg/mL
🏭 Manufacturer	Eris Lifesciences Ltd.
💉 Form	Subcutaneous Injection (Pre-filled Pen)
📦 Packaging	3 mL in 1 pre-filled disposable pen
🩺 Indication	Type 2 Diabetes Mellitus; Obesity Management (off-label)
🇺🇸 US Brand	Victoza (Liraglutide)
⏱️ Delivery Time	6 to 15 days

🧬 Introduction – What Is ERLY (Liraglutide) 6mg/mL?

ERLY 6mg/mL by Eris Lifesciences is an advanced GLP-1 receptor agonist therapy in the form of a pre-filled injectable pen. With each 3 mL pen delivering precise subcutaneous doses of Liraglutide, ERLY is designed for daily diabetes control and increasingly used off-label for obesity management.

It mimics natural incretin hormones to improve insulin secretion, slow gastric emptying, and reduce appetite, making it a powerful choice for managing blood sugar and assisting weight loss.

Manufactured in India, ERLY offers a cost-effective alternative to Victoza, with similar pharmacological action and dosage patterns, suitable for international patients seeking access to trusted GLP-1 treatments.

🎥 Video Overview – Liraglutide Mechanism & Usage (ERLY Pen)

📺 “ERLY Liraglutide: Diabetes & Weight Control with GLP-1 Agonists”

🎬 Video Placeholder – Explains injection method, dosage escalation, and benefits of GLP-1 therapy.

Tip: Inject ERLY subcutaneously in the abdomen, thigh, or upper arm. Use at the same time daily.

🩺 Clinical Benefits of ERLY (Liraglutide)

Improves glycemic control in Type 2 diabetes
Supports gradual and sustainable weight loss (off-label)
May reduce cardiovascular risk factors in diabetic patients
Delays progression to insulin therapy in early disease

💡 Dosage Guidelines

🕒 Therapy Stage	💊 Dosage Recommendation
Initiation Phase	Start with 0.6 mg once daily for one week
Maintenance	Increase to 1.2 mg/day; max 1.8 mg based on tolerance
Injection Route	Subcutaneous (daily)

Do not mix with insulin in the same injection. Rotate sites to reduce irritation.

⚠️ Side Effects & Precautions

💥 Common Effects	❗ Serious Adverse Events
Nausea, vomiting, heartburn	Acute pancreatitis
Diarrhea, headache	Renal impairment (linked to dehydration)
Appetite suppression	Thyroid C-cell tumors (animal models)

Contraindications: Known history of MTC or MEN2 syndromes.

🧃 Storage & Stability

Store refrigerated (2°C to 8°C) before use
After first use, store below 30°C for up to 30 days
Do not freeze or expose to direct light

🌍 Global Access & Import Guide

🌎 Region	📦 Import Policy	📋 Prescription Requirement
🇺🇸 USA	FDA allows import for personal use	Yes (required)
🇬🇧 UK	MHRA permits individual imports	Yes
🇦🇺 Australia	TGA personal use scheme	Yes

🔗 Related Products (Internal Links)

💊 Medicine	🏭 Manufacturer	📖 Description
Rybelsus 14mg	Novo Nordisk India	Oral GLP-1 therapy, alternative to injectables
Ozempic 1mg	Novo Nordisk	Once-weekly injectable Semaglutide
Victoza Pen	Novo Nordisk	International brand of Liraglutide, similar to ERLY
Lirafit Pen	Glenmark / Novo Nordisk	Affordable Liraglutide injection from India
Jardiance 25mg	Boehringer Ingelheim	Oral antidiabetic used alongside GLP-1 agonists

📚 External Resources

FDA Drug Database – Liraglutide
Eris Lifesciences Official Site
NHS GLP-1 Guidelines
PubMed – Clinical Studies on Liraglutide

🩺 Doctor Insight – Dr. Aarti Malekar, MD (Endocrinology)

“ERLY delivers the same metabolic efficiency as Victoza but at a more accessible price point. It’s ideal for patients requiring once-daily GLP-1 therapy and helps improve both sugar control and appetite regulation.”

⚠️ Disclaimer

This content is intended for informational purposes only. ERLY (Liraglutide) is a prescription medication. Always consult your physician before use. Follow all import regulations in your country.